Relay Therapeutics (RLAY) Share-based Compensation (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Share-based Compensation data on file, last reported at $10.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $10.5 million, down 45.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.3 million (down 40.09% YoY), and the FY2025 annual result was $62.4 million, down 33.69% from the prior year.
• Share-based Compensation retreated to $10.5 million in Q1 2026 per RLAY's latest filing, from $13.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $27.2 million in Q1 2024 and troughed at $5.2 million in Q2 2025.
• A 5-year average of $16.0 million and a median of $15.1 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 2202.83% in 2022, then tumbled 66.75% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $13.8 million in 2022, then jumped by 39.44% to $19.3 million in 2023, then declined by 8.47% to $17.6 million in 2024, then slipped by 25.9% to $13.1 million in 2025, then fell by 19.36% to $10.5 million in 2026.
• Business Quant data shows RLAY's Share-based Compensation at $10.5 million in Q1 2026, $13.1 million in Q4 2025, and $9.5 million in Q3 2025.